Abivax (ABVX) shares surge 25% following positive data on experimental bowel disease treatment
Abivax's stock surged 25% following the release of new clinical trial data for its experimental drug obefazimod, which alleviated concerns over cancer risks associated with the treatment. This rebound is significant for investors, as it indicates renewed confidence in the company's prospects after a prior steep decline.